arrow
L

Lukas Delasos

cleveland clinic taussig cancer center
H指数:13
被引数:926

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Trends in treatment and survival of stage IV non-squamous NSCLC from 2010 to 2022

2010年至2022年IV期非鳞状NSCLC的治疗趋势与生存状况

2026-07-310
OA
Long-term outcomes of Extensive-Stage small cell lung cancer treated with chemotherapy or Chemo-immunotherapy: A propensity score adjusted cohort study

广泛期小细胞肺癌经化疗或化疗免疫疗法治疗后的长期结局:一项倾向性评分调整队列研究

2025-11-190
PRE
Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations (vol 4, pg 1345, 2023)
2023-10-091
OAAI
Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations
2023-09-2111
OAAI
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

KRASG12C抑制剂在晚期NSCLC中的疗效和作用

2023-04-1765
OA
Molecular determinants of KRAS p.G12C inhibitor efficacy in advanced NSCLC
2023-04-040
PRE
Novel patient-derived models of desmoplastic small round cell tumor confirm a targetable dependency on ERBB signaling
2022-01-2715
OAAI
The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic NRG1 Fusions

Anti-HER3单克隆抗体Seribantumab可有效抑制患者来源的和同基因细胞系以及致癌NRG1融合的异种移植模型的生长

2021-04-0630
OA
RET inhibition in novel patient-derived models of RET fusion-positive lung adenocarcinoma reveals a role for MYC upregulation

RET融合阳性肺腺癌的新型患者衍生模型中的RET抑制揭示了MYC上调的作用

2021-02-1112
OAAI
MET Exon 14-altered Lung Cancers and MET Inhibitor Resistance

MET外显子14改变的肺癌和MET抑制剂耐药

2021-02-0140
OAAI
Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers
2018-05-31153
OAAI